211 related articles for article (PubMed ID: 17348835)
1. Mycobacterial shikimate pathway enzymes as targets for drug design.
Ducati RG; Basso LA; Santos DS
Curr Drug Targets; 2007 Mar; 8(3):423-35. PubMed ID: 17348835
[TBL] [Abstract][Full Text] [Related]
2.
Nunes JES; Duque MA; de Freitas TF; Galina L; Timmers LFSM; Bizarro CV; Machado P; Basso LA; Ducati RG
Molecules; 2020 Mar; 25(6):. PubMed ID: 32168746
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Structural studies of shikimate 5-dehydrogenase from Mycobacterium tuberculosis.
Arcuri HA; Borges JC; Fonseca IO; Pereira JH; Neto JR; Basso LA; Santos DS; de Azevedo WF
Proteins; 2008 Aug; 72(2):720-30. PubMed ID: 18260104
[TBL] [Abstract][Full Text] [Related]
5. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
6. Identification of shikimate kinase inhibitors among anti-Mycobacterium tuberculosis compounds by LC-MS.
Simithy J; Reeve N; Hobrath JV; Reynolds RC; Calderón AI
Tuberculosis (Edinb); 2014 Mar; 94(2):152-8. PubMed ID: 24429106
[TBL] [Abstract][Full Text] [Related]
7. Functional shikimate dehydrogenase from Mycobacterium tuberculosis H37Rv: purification and characterization.
Fonseca IO; Magalhães ML; Oliveira JS; Silva RG; Mendes MA; Palma MS; Santos DS; Basso LA
Protein Expr Purif; 2006 Apr; 46(2):429-37. PubMed ID: 16298142
[TBL] [Abstract][Full Text] [Related]
8. Understanding the structure, activity and inhibition of chorismate synthase from Mycobacterium tuberculosis.
Arcuri HA; Palma MS
Curr Med Chem; 2011; 18(9):1311-7. PubMed ID: 21366532
[TBL] [Abstract][Full Text] [Related]
9. Cloning and expression of functional shikimate dehydrogenase (EC 1.1.1.25) from Mycobacterium tuberculosis H37Rv.
Magalhães ML; Pereira CP; Basso LA; Santos DS
Protein Expr Purif; 2002 Oct; 26(1):59-64. PubMed ID: 12356471
[TBL] [Abstract][Full Text] [Related]
10. Structure of shikimate kinase from Mycobacterium tuberculosis reveals the binding of shikimic acid.
Pereira JH; de Oliveira JS; Canduri F; Dias MV; Palma MS; Basso LA; Santos DS; de Azevedo WF
Acta Crystallogr D Biol Crystallogr; 2004 Dec; 60(Pt 12 Pt 2):2310-9. PubMed ID: 15583379
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
12. Molecular model of shikimate kinase from Mycobacterium tuberculosis.
Filgueira de Azevedo W; Canduri F; Simões de Oliveira J; Basso LA; Palma MS; Pereira JH; Santos DS
Biochem Biophys Res Commun; 2002 Jul; 295(1):142-8. PubMed ID: 12083781
[TBL] [Abstract][Full Text] [Related]
13. Structure-and-mechanism-based design and discovery of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors.
Yao Y; Li ZS
Curr Top Med Chem; 2014; 14(1):51-63. PubMed ID: 24236726
[TBL] [Abstract][Full Text] [Related]
14. Experiences with the shikimate-pathway enzymes as targets for rational drug design.
Coggins JR; Abell C; Evans LB; Frederickson M; Robinson DA; Roszak AW; Lapthorn AP
Biochem Soc Trans; 2003 Jun; 31(Pt 3):548-52. PubMed ID: 12773154
[TBL] [Abstract][Full Text] [Related]
15. Purine Salvage Pathway in Mycobacterium tuberculosis.
Ducati RG; Breda A; Basso LA; Santos DS
Curr Med Chem; 2011; 18(9):1258-75. PubMed ID: 21366536
[TBL] [Abstract][Full Text] [Related]
16. Cloning and overexpression in soluble form of functional shikimate kinase and 5-enolpyruvylshikimate 3-phosphate synthase enzymes from Mycobacterium tuberculosis.
Oliveira JS; Pinto CA; Basso LA; Santos DS
Protein Expr Purif; 2001 Aug; 22(3):430-5. PubMed ID: 11483005
[TBL] [Abstract][Full Text] [Related]
17. Kinetic mechanism determination and analysis of metal requirement of dehydroquinate synthase from Mycobacterium tuberculosis H37Rv: an essential step in the function-based rational design of anti-TB drugs.
de Mendonça JD; Adachi O; Rosado LA; Ducati RG; Santos DS; Basso LA
Mol Biosyst; 2011 Jan; 7(1):119-28. PubMed ID: 20978656
[TBL] [Abstract][Full Text] [Related]
18. Molecular models for shikimate pathway enzymes of Xylella fastidiosa.
Arcuri HA; Canduri F; Pereira JH; da Silveira NJ; Camera Júnior JC; de Oliveira JS; Basso LA; Palma MS; Santos DS; de Azevedo Júnior WF
Biochem Biophys Res Commun; 2004 Jul; 320(3):979-91. PubMed ID: 15240145
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification and properties of shikimate dehydrogenase from Mycobacterium tuberculosis.
Zhang X; Zhang S; Hao F; Lai X; Yu H; Huang Y; Wang H
J Biochem Mol Biol; 2005 Sep; 38(5):624-31. PubMed ID: 16202245
[TBL] [Abstract][Full Text] [Related]
20. Shikimate kinase: a potential target for development of novel antitubercular agents.
Pereira JH; Vasconcelos IB; Oliveira JS; Caceres RA; de Azevedo WF; Basso LA; Santos DS
Curr Drug Targets; 2007 Mar; 8(3):459-68. PubMed ID: 17348838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
